Dataset Information


Vitamin D?supplementation in Batswana children and adults with HIV: a pilot double blind randomized controlled trial.

ABSTRACT: Since vitamin D insufficiency is common worldwide in people with HIV, we explored safety and efficacy of high dose cholecalciferol (D?) in Botswana, and evaluated potential modifiers of serum 25 hydroxy vitamin D change (?25D).Prospective randomized double-blind 12-week pilot trial of subjects ages 5.0-50.9 years.Sixty subjects randomized within five age groups to either 4000 or 7000 IU per day of D? and evaluated for vitamin D, parathyroid hormone, HIV, safety and growth status. Efficacy was defined as serum 25 hydroxy vitamin D (25D) ?32 ng/mL, and safety as no simultaneous elevation of serum calcium and 25D. Also assessed were HIV plasma viral RNA viral load (VL), CD4%, anti-retroviral therapy (ART) regime, and height-adjusted (HAZ), weight-adjusted (WAZ) and Body Mass Index (BMIZ) Z scores.Subjects were 50% male, age (mean±SD) 19.5±11.8 years, CD4% 31.8±10.4, with baseline VL log?? range of <1.4 to 3.8 and VL detectable (>1.4) in 22%. From baseline to 12 weeks, 25D increased from 36±9 ng/ml to 56±18 ng/ml (p<0.0001) and 68% and 90% had 25D ?32 ng/ml, respectively (p = 0.02). ?25D was similar by dose. No subjects had simultaneously increased serum calcium and 25D. WAZ and BMIZ improved by 12 weeks (p<0.04). HAZ and CD4% increased and VL decreased in the 7000 IU/d group (p<0.04). Younger (5-13y) and older (30-50y) subjects had greater ?25D than those 14-29y (26±17 and 28±12 vs. 11±11 ng/ml, respectively, p?0.001). ?25D was higher with efavirenz or nevirapine compared to protease inhibitor based treatment (22±12, 27±17, vs. 13±10, respectively, p?0.03).In a pilot study in Botswana, 12-week high dose D? supplementation was safe and improved vitamin D, growth and HIV status; age and ART regimen were significant effect modifiers.ClinicalTrials.gov NCT02189902.

SUBMITTER: Steenhoff AP 

PROVIDER: S-EPMC4338235 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5916742 | BioStudies
2019-01-01 | S-EPMC6599740 | BioStudies
2017-01-01 | S-EPMC5686571 | BioStudies
2017-01-01 | S-EPMC5460735 | BioStudies
2016-01-01 | S-EPMC4971338 | BioStudies
1000-01-01 | S-EPMC4661572 | BioStudies
2020-01-01 | S-EPMC7209323 | BioStudies
2015-01-01 | S-EPMC4686255 | BioStudies
2019-01-01 | S-EPMC6620502 | BioStudies
2014-01-01 | S-EPMC4126892 | BioStudies